Professor Louise Bowman
BA, MBBS, MD, FRCP
Professor of Medicine & Clinical Trials, and Honorary Consultant Physician (Lipidology)
- Clinical Trial Service Unit
- MRC PHRU Programme Leader
Louise Bowman is Professor of Medicine and Clinical Trials at the Clinical Trial Service Unit of the University of Oxford. Her specialist clinical background is in Diabetes and Endocrinology. She has particular research interests in cardiovascular disease in diabetes, and maintains her clinical practice with regular specialist lipid clinics. She is Chief Investigator for the ORION-4 trial which will assess the effects of inclisiran on clinical outcomes among 15,000 people with atherosclerotic cardiovascular disease, and for the AMALFI trial, which will assess the value of screening for undiagnosed atrial fibrillation in high-risk individuals.
Prof Bowman is also Co-principal Investigator for the recently-reported ASCEND trial, which studied the effects of aspirin and of omega-3 fatty acid supplementation for the primary prevention of cardiovascular disease in 15,000 people with diabetes, and for the REVEAL study, an international clinical trial that assessed the efficacy and safety of the CETP-inhibitor, anacetrapib, in 30,000 high-risk individuals.
Through her work on large-scale trials in cardiovascular disease she has developed a specialist interest in Clinical Trials Methodology and is Director of the Oxford CTSU Hub for the MRC Network of Hubs for Trials Methodology Research (HTMR). Her focus is on the development, application and widespread promotion of methods to enhance the design and conduct of trials to ensure high quality outputs and reliable results at low cost.
ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
Bowman L. et al, (2018), Am heart j, 198, 135 - 144
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group None. et al, (2017), N engl j med, 377, 1217 - 1227
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
REVEAL Collaborative Group None. et al, (2017), Am heart j, 187, 182 - 190
Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol
Llewellyn-Bennett RE. et al, (2016), Systematic reviews
Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
Aung T. et al, (2016), Trials, 17